Modernizing the PMP: Updates to the Iowa Prescription Drug Monitoring Program
Medication prescribers and dispensers in the state of Iowa.
On May 14, 2018, IA HF 2377 addressing the problem with opioid abuse and addiction at several angles including the standpoint of curving prescription abuse was signed in law. This law requires prescribers to register for Iowa’s prescription drug monitoring program (PMP) and report any controlled substance they give to patients in the PMP. Physician and non-physician prescribers must have knowledge of these new requirements.
The Iowa Prescription Monitoring Program has launched significant updates and enhancements in 2018. This continuing education course will explain the functionality and purpose of the PMP, and guide prescribers and dispensers of medications in Iowa through the process to have a positive impact on healthcare in Iowa.
- Identify updates and enhancements made to the Iowa Prescription Monitoring Program (PMP) in 2018.
- Explain the application NarxCare, including its functionality and purpose.
- Recognize the appropriate contacts and methods for initiating the integration of the PMP into electronic health records (eHRs) and pharmacy dispensing software (PDS).
- List the changes to rules and legislation in 2018 surrounding the PMP and explain the impact it may have on the healthcare community.
Andrew Funk, PharmD
Executive Director, Iowa Board of Pharmacy
Continuing Education Credit
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 1.0 AOA Category 2-B credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and the Iowa Medical Society. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this internet enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Other Health Professionals: This live activity is designated for 1.0 AMA PRA Category 1 Credit(s)TM.
No commercial interest company provided financial support for this continuing education activity.
Everyone in a position to control the content of this educational activity will disclose to the CME provider and to attendees all relevant financial relationships with any commercial interest. They will also disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director. Firms providing financial support did not have input in these areas. The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 1.00 AOA Category 2B
- 1.00 AMA PRA Category 1 Credits™
- 1.00 CE Contact Hour(s)